% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • zba5552003 zba5552003 Nov 5, 2012 9:57 AM Flag


    Under the amended terms of the agreement Isis will receive a $2.5 million upfront payment and is eligible to earn a $7.5 million milestone payment upon the initiation of the ISIS-TTRRx Phase 2/3 study. Isis is also eligible to earn an additional $50 million in pre-licensing milestone payments to support the ISIS-TTRRx Phase 2/3 study. In addition, GSK has increased the regulatory and sales milestones payable to Isis should the product achieve registration and meet certain sales thresholds. Isis will also receive double-digit royalties on sales of ISIS-TTRRx

63.37+2.22(+3.63%)Mar 27 4:00 PMEDT